Merck Faces Multiple Challenges: Will It Steer Through Successfully?

Merck (MRK) faces significant long-term growth challenges, primarily the anticipated loss of exclusivity for its top-selling drug, Keytruda (50% of sales), in 2028, compounded by Medicare drug pricing impacts under the Inflation Reduction Act affecting Keytruda from 2028 and Januvia from 2026. Further headwinds include a 40% decline in Gardasil sales in Q1 2025 due to weak China demand. However, the company is strategically positioning new products like Capvaxive and Winrevair, which have launched strongly, and diversifying its non-oncology portfolio to offset these pressures. While MRK shares are down 18.2% year-to-date, its valuation appears attractive relative to the industry.

Analysis

Merck faces a significant and clearly defined long-term revenue challenge centered on the 2028 loss of exclusivity for its flagship drug, Keytruda, which constitutes approximately 50% of company sales. While Keytruda's sales remain a key growth driver, rising 6% year-over-year to $7.21 billion in Q1 2025, its projected 5.4% CAGR over the next three years highlights a decelerating trajectory ahead of the patent cliff. This primary headwind is compounded by two other material factors: the sharp decline in Gardasil sales and impending regulatory pricing pressures. Gardasil revenue fell 40% in Q1 2025, driven by weak demand in China, and is projected to have a negative 6.4% CAGR over the next three years, eroding a key secondary revenue stream. Furthermore, the Inflation Reduction Act (IRA) is set to impact Januvia pricing in 2026 and Keytruda in 2028, creating a structural drag on revenue. In response, Merck's strategy hinges on the successful commercialization of new products like Capvaxive and Winrevair, which have had strong initial launches. Despite this strategic pivot, the market has priced in significant risk, with shares down 18.2% year-to-date. However, this has resulted in a valuation of 8.71 times forward earnings, a steep discount to both its industry peer group (14.93) and its own 5-year average (12.83), reflecting a deep-seated investor concern that is also mirrored in recent downward revisions to 2025 and 2026 earnings estimates.

Key Decisions for Investors

• Investors should weigh Keytruda's near-term revenue stability against the well-defined 2028 patent cliff and escalating pricing pressures from the IRA, which will begin impacting other products like Januvia as early as 2026.
• The current forward P/E of 8.71 suggests a potential value opportunity, as a significant portion of the long-term headwinds may already be priced into the stock, making it attractive for those confident in the pipeline's ability to offset the Keytruda decline.
• Closely monitor the early sales performance and market uptake of new launches Capvaxive and Winrevair, as their success is the primary catalyst to mitigate the impending Keytruda revenue gap.
• Given the 40% Q1 sales drop for Gardasil in China, investors should track whether this regional demand weakness remains contained or begins to affect sales in other strong markets like the United States and Japan.